Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diflunisal in transthyretin cardiac amyloidosis
2019-002873-80Phase 2Active
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of diflunisal in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoint: Change in extracellular volume by cardiac MRI T1 mapping. Started Nov 2019; status: active.
02
Drugs
diflunisal
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2019-002873-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002873-80.